-
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HYP2090PTSA. This small molecule KRAS G12C/PI3K inhibitor is intended for the treatment of advanced solid tumors with KRAS G12C…
-
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
•
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement with fellow Chinese firm LanssonPharm. The agreement grants Livzon exclusive rights to Lansson’s phosphodiesterase 4 (PDE4) inhibitor, LS21031, in Greater China, marking a strategic move to expand Livzon’s portfolio in the mental health space. Terms…
-
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
•
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the treatment of moderate-to-severe atopic dermatitis, a skin condition characterized by inflammation and itching. The data, released this week, highlights the drug’s performance over an extended period of two years. Sustained Efficacy in Atopic DermatitisThe primary…
-
China’s Healthcare Landscape: Key Insights from the 2022 Statistical Communique
•
The National Health Commission (NHC) has released “China’s Healthcare Statistical Communique 2022,” providing a comprehensive overview of the country’s healthcare sector. The annual report reveals a growth in medical and health institutions, an increase in national health expenditure, and detailed insights into the distribution of healthcare costs. Expansion of Medical…
-
Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced positive topline results from the Phase III mini CHAMP study for NVK002, an atropine external use eye solution developed to address myopia progression. Study Design and ParticipantsThe Phase III mini CHAMP study was…
-
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
•
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE: JNJ) has received two tacit clinical trial approvals for its Category 1 drug cetrelimab combined with TAR-200. The approvals are for the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) patients not receiving BCG treatment, and…
-
Nanjing Geneseeq’s NSCLC TMB Detection Kit Approved by NMPA
•
China-based Nanjing Geneseeq Medical Device and Diagnostic Inc. has announced that its tissue tumor mutation burden (TMB) detection kit, utilizing a reversible end termination sequencing method, has received marketing approval from the National Medical Products Administration (NMPA). This marks the kit as the 231st novel medical device approved in China.…
-
RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer
•
China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its antibody-drug conjugate (ADC) candidate, disitamab vedotin (RC48), in patients with breast cancer. First Home-Grown ADC with Conditional Approvals Disitamab vedotin stands…
